Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Paola Muñoz-López; Rosa María Ribas-Aparicio; Elayne Irene Becerra-Báez; Karla Fraga-Pérez; Luis Fernando Flores-Martínez; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez

doi:10.3390/cancers14174206

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Paola Muñoz-López, Rosa María Ribas-Aparicio, Elayne Irene Becerra-Báez, Karla Fraga-Pérez, Luis Fernando Flores-Martínez, Armando Alfredo Mateos-Chávez, Rosendo Luria-Pérez

Escuela Nacional de Ciencias Biológicas (ENCB)

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.

Original language	English
Article number	4206
Journal	Cancers
Volume	14
Issue number	17
DOIs	https://doi.org/10.3390/cancers14174206
State	Published - Sep 2022

Keywords

cancer therapy
immunotherapy
single-chain fragment variable

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers14174206

Cite this

@article{ab18c690967f419b937abcb81395c45d,

title = "Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy",

abstract = "Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.",

keywords = "cancer therapy, immunotherapy, single-chain fragment variable",

author = "Paola Mu{\~n}oz-L{\'o}pez and Ribas-Aparicio, {Rosa Mar{\'i}a} and Becerra-B{\'a}ez, {Elayne Irene} and Karla Fraga-P{\'e}rez and Flores-Mart{\'i}nez, {Luis Fernando} and Mateos-Ch{\'a}vez, {Armando Alfredo} and Rosendo Luria-P{\'e}rez",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/cancers14174206",

language = "Ingl{\'e}s",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

number = "17",

}

TY - JOUR

T1 - Single-Chain Fragment Variable

T2 - Recent Progress in Cancer Diagnosis and Therapy

AU - Muñoz-López, Paola

AU - Ribas-Aparicio, Rosa María

AU - Becerra-Báez, Elayne Irene

AU - Fraga-Pérez, Karla

AU - Flores-Martínez, Luis Fernando

AU - Mateos-Chávez, Armando Alfredo

AU - Luria-Pérez, Rosendo

PY - 2022/9

Y1 - 2022/9

N2 - Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.

AB - Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.

KW - cancer therapy

KW - immunotherapy

KW - single-chain fragment variable

UR - http://www.scopus.com/inward/record.url?scp=85137818434&partnerID=8YFLogxK

U2 - 10.3390/cancers14174206

DO - 10.3390/cancers14174206

M3 - Artículo de revisión

C2 - 36077739

AN - SCOPUS:85137818434

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 17

M1 - 4206

ER -

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this